AbbVie Inc. revealed in a statement it will be acquiring Cerevel Therapeutics Hldg in an agreement valued at $8.7 billion or $45 per share.
The deal is expected to boost AbbVie's neuroscience portfolio, as it will add "a wide range of potentially best-in-class assets that may transform standards of care...
AbbVie Inc. said on Thursday that it will pay $10.1 billion to acquire ImmunoGen Inc. and its flagship cancer treatment, Elahere, which is used to treat ovarian cancer. The transaction is anticipated to close in the middle of 2024.
"The acquisition of ImmunoGen demonstrates our commitment to...
European Commission announced on Friday it greenlighted biopharmaceutical company AbbVie Inc's purchase of pharmaceutical company Allergan Plc.
EU's competition commissioner Margrethe Vestager said the acquisition "will increase the choice of treatments and offer better prices for...
Biopharmaceutical company AbbVie Inc. will acquire pharmaceutical giant Allergan Plc for roughly $63 billion in a cash-and-stock deal, the former announced in a press release on Tuesday.
Under the terms of the deal, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
